IL157898A0 - Antineoplastic combinations such as rapamycin together with gemcitabine or fluorouracil - Google Patents
Antineoplastic combinations such as rapamycin together with gemcitabine or fluorouracilInfo
- Publication number
- IL157898A0 IL157898A0 IL15789802A IL15789802A IL157898A0 IL 157898 A0 IL157898 A0 IL 157898A0 IL 15789802 A IL15789802 A IL 15789802A IL 15789802 A IL15789802 A IL 15789802A IL 157898 A0 IL157898 A0 IL 157898A0
- Authority
- IL
- Israel
- Prior art keywords
- fluorouracil
- gemcitabine
- rapamycin
- antineoplastic combinations
- rapamycin together
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US28238801P | 2001-04-06 | 2001-04-06 | |
US28238501P | 2001-04-06 | 2001-04-06 | |
PCT/US2002/010912 WO2002080975A1 (en) | 2001-04-06 | 2002-04-05 | Antineoplastic combinations such as rapamycin together with gemcitabine or fluorouracil |
Publications (1)
Publication Number | Publication Date |
---|---|
IL157898A0 true IL157898A0 (en) | 2004-03-28 |
Family
ID=26961412
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL15789802A IL157898A0 (en) | 2001-04-06 | 2002-04-05 | Antineoplastic combinations such as rapamycin together with gemcitabine or fluorouracil |
Country Status (22)
Country | Link |
---|---|
EP (1) | EP1385551B1 (ja) |
JP (1) | JP2004525950A (ja) |
KR (1) | KR100862178B1 (ja) |
CN (1) | CN1309421C (ja) |
AT (1) | ATE406892T1 (ja) |
AU (1) | AU2007242958A1 (ja) |
BR (1) | BR0208627A (ja) |
CA (1) | CA2442849A1 (ja) |
DE (1) | DE60228699D1 (ja) |
EA (1) | EA010184B1 (ja) |
ES (1) | ES2312568T3 (ja) |
HK (1) | HK1060062A1 (ja) |
HU (1) | HUP0304093A3 (ja) |
IL (1) | IL157898A0 (ja) |
MX (1) | MXPA03009092A (ja) |
NO (1) | NO20034433L (ja) |
NZ (1) | NZ540047A (ja) |
PL (1) | PL363991A1 (ja) |
PT (1) | PT1385551E (ja) |
SG (1) | SG152906A1 (ja) |
SI (1) | SI1385551T1 (ja) |
WO (1) | WO2002080975A1 (ja) |
Families Citing this family (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HU230302B1 (hu) | 2000-10-20 | 2015-12-28 | Eisai R&D Management Co., Ltd. | Nitrogéntartalmú aromás származékok és ezeket tartalmazó gyógyászati készítmények |
PT2762140T (pt) | 2001-02-19 | 2017-07-04 | Novartis Ag | Resumo |
GB0124577D0 (en) * | 2001-10-12 | 2001-12-05 | Novartis Forschungsstiftung | Novel methods |
IL162734A0 (en) | 2002-02-01 | 2005-11-20 | Ariad Gene Therapeutics Inc | Phosphorus-containing compounds & uses thereof |
UA83484C2 (uk) * | 2003-03-05 | 2008-07-25 | Уайт | Спосіб лікування раку грудей комбінацією похідного рапаміцину і інгібітора ароматази - летрозолу, фармацевтична композиція |
CN101337930B (zh) | 2003-11-11 | 2010-09-08 | 卫材R&D管理有限公司 | 脲衍生物的制备方法 |
EP1732583A4 (en) * | 2004-02-26 | 2009-08-12 | Penn State Res Found | COMBINATORIES THERAPY FOR THE TREATMENT OF NEOPLASIA USING OPIOID GROWTH FACTOR RECEPTORS |
WO2006027545A2 (en) * | 2004-09-10 | 2006-03-16 | Agency For Science, Technology And Research | Method |
ATE428421T1 (de) | 2004-09-17 | 2009-05-15 | Eisai R&D Man Co Ltd | Medizinische zusammensetzung mit verbesserter stabilität und reduzierten gelierungseigenschaften |
CN102886045A (zh) | 2005-02-03 | 2013-01-23 | 综合医院公司 | 治疗吉非替尼耐药性癌症的方法 |
WO2007015578A1 (ja) | 2005-08-02 | 2007-02-08 | Eisai R & D Management Co., Ltd. | 血管新生阻害物質の効果を検定する方法 |
EP1942937A1 (en) * | 2005-11-04 | 2008-07-16 | Wyeth | Antineoplastic combinations with mtor inhibitor, herceptin, and/or hki-272 |
WO2007059106A2 (en) * | 2005-11-14 | 2007-05-24 | Ariad Gene Therapeutics, Inc. | Administration of mntor inhibitor to treat patients with cancer |
CA2933875C (en) | 2005-11-21 | 2018-06-26 | Novartis Ag | 40-o-(2-hydroxyethyl)-rapamycin for use as a sole drug substance in the treatment of carcinoid tumors arising from the foregut, midgut, or hindgut |
GB0523658D0 (en) * | 2005-11-21 | 2005-12-28 | Novartis Ag | Organic compounds |
KR20080085213A (ko) * | 2006-01-12 | 2008-09-23 | 노파르티스 아게 | Mtor 억제제 및 항엽산 화합물의 조합물 |
EP1880723A1 (en) * | 2006-07-14 | 2008-01-23 | Novartis AG | Combination of mTOR inhibitor and antifolate compound |
WO2007106503A2 (en) | 2006-03-13 | 2007-09-20 | Osi Pharmaceuticals, Inc. | Combined treatment with an egfr kinase inhibitor and an agent that sensitizes tumor cells to the effects of egfr kinase inhibitors |
EP2591775A1 (en) * | 2006-04-05 | 2013-05-15 | Novartis AG | Combinations comprising mtor inhibitors for treating cancer |
RU2448708C3 (ru) | 2006-05-18 | 2017-09-28 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Противоопухолевое средство против рака щитовидной железы |
JP2009539769A (ja) * | 2006-06-02 | 2009-11-19 | アリアド ジーン セラピューティクス インコーポレイテッド | カペシタビン併用療法 |
US20100266590A1 (en) * | 2006-08-02 | 2010-10-21 | Demetri George D | Combination therapy |
KR101472600B1 (ko) | 2006-08-28 | 2014-12-15 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 미분화형 위암에 대한 항종양제 |
JP5919593B2 (ja) * | 2006-10-11 | 2016-05-18 | フージョン アンティボディーズ リミテッド | 併用療法 |
CA2669415A1 (en) | 2006-11-14 | 2008-05-22 | Ariad Pharmaceuticals, Inc. | Solid dosage form comprising ap23573 |
JPWO2008088088A1 (ja) | 2007-01-19 | 2010-05-13 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 膵癌治療用組成物 |
WO2008093855A1 (ja) | 2007-01-29 | 2008-08-07 | Eisai R & D Management Co., Ltd. | 未分化型胃癌治療用組成物 |
DK2481402T3 (en) * | 2007-03-07 | 2018-08-06 | Abraxis Bioscience Llc | Nanoparticle comprising rapamycin and albumin as anticancer agent |
ES2435452T3 (es) | 2007-06-01 | 2013-12-19 | Abraxis Bioscience, Llc | Métodos y composiciones para tratar un cáncer recurrente |
US8022216B2 (en) | 2007-10-17 | 2011-09-20 | Wyeth Llc | Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof |
WO2009060945A1 (ja) | 2007-11-09 | 2009-05-14 | Eisai R & D Management Co., Ltd. | 血管新生阻害物質と抗腫瘍性白金錯体との併用 |
WO2009117669A2 (en) | 2008-03-21 | 2009-09-24 | The University Of Chicago | Treatment with opioid antagonists and mtor inhibitors |
PL2310011T3 (pl) | 2008-06-17 | 2013-12-31 | Wyeth Llc | Kombinacje przeciwnowotworowe zawierające HKI-272 i vinorelbine |
SG10202102855RA (en) | 2008-08-04 | 2021-05-28 | Wyeth Llc | Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine |
MX356593B (es) | 2009-04-06 | 2018-06-05 | Wyeth Llc | Régimen de tratamiento que utiliza neratinib para cáncer de mama. |
BR112012032462A2 (pt) | 2010-06-25 | 2016-11-08 | Eisai R&D Man Co Ltd | agente antitumoral empregando compostos que, em combinação, têm efeito inibidor de quinase. |
CN103402519B (zh) | 2011-04-18 | 2015-11-25 | 卫材R&D管理有限公司 | 肿瘤治疗剂 |
JP6038128B2 (ja) | 2011-06-03 | 2016-12-07 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | レンバチニブ化合物に対する甲状腺癌対象及び腎臓癌対象の反応性を予測及び評価するためのバイオマーカー |
CN104755463A (zh) | 2012-12-21 | 2015-07-01 | 卫材R&D管理有限公司 | 非晶态形式的喹啉衍生物及其生产方法 |
MX368099B (es) | 2013-05-14 | 2019-09-19 | Eisai R&D Man Co Ltd | Biomarcadores para predecir y evaluar el grado de respuesta de sujetos con cancer de endometrio a compuestos de tipo lenvatinib. |
KR102329681B1 (ko) | 2014-08-28 | 2021-11-23 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 고순도의 퀴놀린 유도체 및 이를 제조하는 방법 |
BR112017017428A2 (ja) | 2015-02-25 | 2018-04-03 | Eisai R&D Management Co., Ltd. | A bitter taste inhibition method of a quinoline derivative |
CA2978226A1 (en) | 2015-03-04 | 2016-09-09 | Merck Sharpe & Dohme Corp. | Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer |
BR112017027227B1 (pt) | 2015-06-16 | 2023-12-12 | Eisai R&D Management Co., Ltd | Agente anti-câncer |
FI3436461T3 (fi) | 2016-03-28 | 2024-01-16 | Incyte Corp | Pyrrolotriatsiiniyhdisteitä tam-inhibiittoreina |
US11241438B2 (en) | 2018-06-29 | 2022-02-08 | Incyte Corporation | Formulations of an AXL/MER inhibitor |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5066493A (en) * | 1978-11-03 | 1991-11-19 | American Home Products Corporation | Rapamycin in treatment of tumors |
BE877700A (fr) * | 1978-11-03 | 1980-01-14 | Ayerst Mckenna & Harrison | Compositions pharmaceutiques a base de rapamycine pour le traitement de tumeurs carcinogenes |
US5362718A (en) * | 1994-04-18 | 1994-11-08 | American Home Products Corporation | Rapamycin hydroxyesters |
NZ336676A (en) * | 1997-01-24 | 2000-01-28 | Norsk Hydro As | Gemcitabine esters or amides useful as anti-cancer and anti-viral agents |
TW466112B (en) * | 1998-04-14 | 2001-12-01 | Lilly Co Eli | Novel use of 2'-deoxy-2',2'-difluorocytidine for immunosuppressive therapy and pharmaceutical composition comprising the same |
-
2002
- 2002-04-05 IL IL15789802A patent/IL157898A0/xx unknown
- 2002-04-05 EA EA200301091A patent/EA010184B1/ru not_active IP Right Cessation
- 2002-04-05 SI SI200230737T patent/SI1385551T1/sl unknown
- 2002-04-05 CN CNB028077490A patent/CN1309421C/zh not_active Expired - Fee Related
- 2002-04-05 ES ES02726710T patent/ES2312568T3/es not_active Expired - Lifetime
- 2002-04-05 NZ NZ540047A patent/NZ540047A/en unknown
- 2002-04-05 MX MXPA03009092A patent/MXPA03009092A/es active IP Right Grant
- 2002-04-05 SG SG200506382-1A patent/SG152906A1/en unknown
- 2002-04-05 DE DE60228699T patent/DE60228699D1/de not_active Expired - Fee Related
- 2002-04-05 PL PL02363991A patent/PL363991A1/xx unknown
- 2002-04-05 HU HU0304093A patent/HUP0304093A3/hu unknown
- 2002-04-05 AT AT02726710T patent/ATE406892T1/de not_active IP Right Cessation
- 2002-04-05 BR BR0208627-1A patent/BR0208627A/pt not_active IP Right Cessation
- 2002-04-05 EP EP02726710A patent/EP1385551B1/en not_active Expired - Lifetime
- 2002-04-05 JP JP2002579013A patent/JP2004525950A/ja active Pending
- 2002-04-05 PT PT02726710T patent/PT1385551E/pt unknown
- 2002-04-05 WO PCT/US2002/010912 patent/WO2002080975A1/en active Application Filing
- 2002-04-05 KR KR1020037013090A patent/KR100862178B1/ko not_active IP Right Cessation
- 2002-04-05 CA CA002442849A patent/CA2442849A1/en not_active Withdrawn
-
2003
- 2003-10-03 NO NO20034433A patent/NO20034433L/no not_active Application Discontinuation
-
2004
- 2004-04-30 HK HK04103071A patent/HK1060062A1/xx not_active IP Right Cessation
-
2007
- 2007-12-13 AU AU2007242958A patent/AU2007242958A1/en not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
NZ540047A (en) | 2007-01-26 |
NO20034433L (no) | 2003-11-25 |
CN1545419A (zh) | 2004-11-10 |
HUP0304093A2 (hu) | 2004-04-28 |
CA2442849A1 (en) | 2002-10-17 |
ATE406892T1 (de) | 2008-09-15 |
PL363991A1 (en) | 2004-11-29 |
EA200301091A1 (ru) | 2004-02-26 |
HUP0304093A3 (en) | 2008-08-28 |
JP2004525950A (ja) | 2004-08-26 |
SI1385551T1 (sl) | 2008-12-31 |
HK1060062A1 (en) | 2004-07-30 |
PT1385551E (pt) | 2008-11-03 |
EP1385551B1 (en) | 2008-09-03 |
EA010184B1 (ru) | 2008-06-30 |
SG152906A1 (en) | 2009-06-29 |
NO20034433D0 (no) | 2003-10-03 |
AU2007242958A1 (en) | 2008-01-10 |
EP1385551A1 (en) | 2004-02-04 |
DE60228699D1 (de) | 2008-10-16 |
KR100862178B1 (ko) | 2008-10-09 |
KR20040007491A (ko) | 2004-01-24 |
MXPA03009092A (es) | 2004-02-12 |
ES2312568T3 (es) | 2009-03-01 |
WO2002080975A1 (en) | 2002-10-17 |
BR0208627A (pt) | 2004-03-09 |
CN1309421C (zh) | 2007-04-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG152906A1 (en) | Antineoplastic combinations such as rapamycin together with gemcitabine or fluorouracil | |
SG170612A1 (en) | Antineoplastic combinations | |
SG148031A1 (en) | Use of cci-779 as an antineoplastic agent | |
ECSP056001A (es) | Combinaciones antineoplásicas | |
CY2008014I2 (el) | Β-αμινο-τετραϋδροϊμιδαζο-(1,2-α)-πυραζινες και τετραϋδροτριαζολο-(4,3-α)-πυραζινες ως αναστολεις της διπεπτιδυλο πεπτιδασης για την αγωγη ή προληψη του διαβητη | |
TW200420573A (en) | Bifunctional heterocyclic compounds and methods of making and using same | |
AU2003237367A8 (en) | Use of nrg4, or inhibitors thereof, in the treatment of colon and pancreatic cancer | |
AU302959S (en) | Toothbrush | |
MXPA05010582A (es) | Combinaciones antineoplasicas. | |
ATE414514T1 (de) | Kombinationen, ein antidiarrhoikum und epothilon oder ein epothilonderivat enthaltend | |
DE60226666D1 (de) | Wälz- und Gleitlagerbauteil und Wälzlager | |
WO2005087265A8 (en) | Antineoplastic combinations of cci-779 and rituximab | |
SG153647A1 (en) | Antineoplastic combinations | |
ECSP034866A (es) | Combinaciones antineoplásticas | |
ECSP034790A (es) | Combinaciones antineoplásticas tales como rapamicin junto con gemcitabina o fluorouracil | |
AU300156S (en) | Underwear |